CRIS Current Research Information System

BROCCOLI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.765
AS - Asia 8.549
EU - Europa 7.871
SA - Sud America 530
Continente sconosciuto - Info sul continente non disponibili 474
AF - Africa 419
OC - Oceania 10
Totale 26.618
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.585
SG - Singapore 2.334
VN - Vietnam 2.211
CN - Cina 2.164
NL - Olanda 2.161
IT - Italia 1.351
DE - Germania 1.042
GB - Regno Unito 946
SE - Svezia 842
HK - Hong Kong 590
BR - Brasile 387
FR - Francia 355
IN - India 323
RU - Federazione Russa 310
KR - Corea 226
IE - Irlanda 191
UA - Ucraina 160
BD - Bangladesh 147
JP - Giappone 139
FI - Finlandia 119
TG - Togo 108
ZA - Sudafrica 104
CI - Costa d'Avorio 93
CA - Canada 87
EE - Estonia 72
PL - Polonia 66
AR - Argentina 59
JO - Giordania 53
TH - Thailandia 49
ID - Indonesia 48
PH - Filippine 44
MX - Messico 39
AT - Austria 38
IQ - Iraq 36
CH - Svizzera 35
NG - Nigeria 35
ES - Italia 34
SC - Seychelles 34
BE - Belgio 28
TW - Taiwan 25
TR - Turchia 24
HR - Croazia 23
IR - Iran 20
BG - Bulgaria 17
EC - Ecuador 17
PK - Pakistan 17
SA - Arabia Saudita 17
UZ - Uzbekistan 14
PY - Paraguay 13
VE - Venezuela 13
CL - Cile 12
CR - Costa Rica 12
MY - Malesia 12
JM - Giamaica 11
PT - Portogallo 11
LT - Lituania 10
RO - Romania 10
KE - Kenya 9
LB - Libano 9
EG - Egitto 8
GR - Grecia 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
CO - Colombia 6
CZ - Repubblica Ceca 6
MA - Marocco 6
PR - Porto Rico 6
RS - Serbia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
OM - Oman 5
HU - Ungheria 4
IL - Israele 4
KZ - Kazakistan 4
MD - Moldavia 4
MK - Macedonia 4
PS - Palestinian Territory 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
HN - Honduras 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
NI - Nicaragua 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
GH - Ghana 2
GY - Guiana 2
KG - Kirghizistan 2
Totale 26.115
Salva come PNG Salva come JPEG
Città #
Singapore 1.615
Eygelshoven 1.296
Ashburn 932
Southend 782
Fairfield 719
Kerkrade 666
Chandler 551
Hong Kong 550
San Jose 506
Ho Chi Minh City 477
Hefei 451
Santa Clara 430
Frankfurt am Main 399
Houston 389
Hanoi 376
Woodbridge 370
Seattle 318
Wilmington 291
Beijing 287
Dong Ket 278
Princeton 241
Ann Arbor 237
Cambridge 224
Bologna 220
Seoul 207
Council Bluffs 198
Dublin 191
Boardman 187
New York 155
Los Angeles 145
Lauterbourg 142
Dallas 130
Milan 126
Tokyo 117
Lomé 108
Abidjan 93
Berlin 91
Helsinki 87
Westminster 87
Nanjing 85
Buffalo 75
Padova 71
Jinan 69
Rome 68
Haiphong 66
Da Nang 60
Jacksonville 59
São Paulo 55
Bremen 54
London 54
Amman 53
Chicago 53
Shenyang 50
Turin 50
Warsaw 48
Changsha 45
Bengaluru 43
San Diego 43
Secaucus 42
Shanghai 42
Saint Petersburg 40
Redondo Beach 39
Falkenstein 38
Kyiv 38
Guangzhou 37
Florence 36
Phoenix 35
Hebei 34
Zhengzhou 34
Dearborn 32
Hangzhou 32
Munich 32
Nanchang 32
Hyderabad 31
Orem 31
Tianjin 30
Toronto 30
Redwood City 29
San Francisco 29
The Dalles 29
Abeokuta 28
Des Moines 28
Jakarta 27
Jiaxing 26
Brussels 25
Lappeenranta 25
Bern 24
Brooklyn 24
Nuremberg 23
Amsterdam 22
Redmond 22
Düsseldorf 21
Johannesburg 21
Baghdad 20
Modena 20
Biên Hòa 17
Catania 17
Hải Dương 17
Olalla 17
Rimini 17
Totale 16.963
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.875
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 471
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 306
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 261
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 258
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 254
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 245
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 244
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 233
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 228
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 226
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 225
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 224
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 221
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 218
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 217
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 210
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 208
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 208
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 206
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 204
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 203
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 201
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 200
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 196
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 195
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 190
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 188
Corso di malattie del sangue e degli organi emolinfopoietici 186
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 184
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 182
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 182
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 182
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 181
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 181
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 180
Living Anatomy 179
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 178
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 177
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 177
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 176
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 176
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 176
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 175
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 175
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 174
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 173
Angioimmunoblastic T-Cell Lymphoma 172
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 170
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 170
Hepato-gastric and spleno-mesenteric arterial trunks: anatomical variation report and review of literature 170
Cutaneous adverse-events in patients treated with Ibrutinib 170
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 169
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 168
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 168
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 168
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 167
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 167
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 165
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 164
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 164
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (Modern Pathology, (2020), 33, 2, (179-187), 10.1038/s41379-019-0279-8) 162
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 160
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 159
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 158
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 157
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 157
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 155
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 155
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 151
Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report 151
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 151
The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. 150
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 149
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 149
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 146
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 146
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease 146
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 145
Genetic and phenotypic attributes of splenic marginal zone lymphoma 144
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 144
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 144
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 142
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 142
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 141
Hepatogastric and splenomesenteric arterial trunks: anatomical variations report 141
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 140
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 139
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 139
PET/CT in Non-Hodgkin Lymphoma: An Update 137
Erythematous induration of the chest 135
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 135
Possible novel agents in marginal zone lymphoma 134
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 134
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 133
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified 133
PET/CT guided biopsy in lymphoma patients 132
Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukaemia patients 130
Totale 20.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.510
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.510
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.914 0 60 122 258 187 110 37 159 74 153 424 330
2022/20232.566 237 371 171 333 213 204 60 191 397 85 162 142
2023/2024889 66 156 76 104 67 113 55 53 28 71 40 60
2024/20254.018 174 497 327 259 567 176 439 121 97 293 213 855
2025/202611.102 748 988 795 635 912 1.764 1.830 271 1.725 758 380 296
2026/2027750 387 363 0 0 0 0 0 0 0 0 0 0
Totale 26.618